Development of novel therapy against glioma stem cells using super catalytic antibodies.

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10337
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurosurgery
• Research Institution: Saga University
• Principal Investigator: Abe Tatsuya 佐賀大学, 医学部, 教授 (40281216)
• Co-Investigator(Kenkyū-buntansha): 宇田 泰三 公益財団法人九州先端科学技術研究所, ナノテク研究室, 特別研究員 (20232837) ; 籾井 泰朋 大分大学, 医学部, 助教 (20534192) ; 河島 雅到 佐賀大学, 医学部, 准教授 (20383565) ; 増岡 淳 佐賀大学, 医学部, 助教 (50359949) ; 中原 由紀子 佐賀大学, 医学部, 講師 (50380770)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 脳腫瘍 / 幹細胞 / スーパー抗体酵素

Outline of Final Research Achievements

Malignant brain tumor shows poor prognosis.MASUOKA any papers about glioblastoma (GBM) stem cells (GSCs) are reported to be an important factor. Our collaborative research produced super catalytic antibodies possessing serine protease-like characteristics. We perfumed screening with various super catalytic antibodies in human glioma cell lines and several GSCs. We found several clones showing anti-tumor effects against human glioma cell lines and GSCs in vitro. One clone against tight junction may suppress GSC’s growth to inhibit sphere formation. However, further studies are required to confirm whether these clones could be new anticancer drug in vivo. We would like to develop novel anticancer agents in brain and other solid tumor through translational research in the future.

Free Research Field

脳腫瘍